Unknown

Dataset Information

0

High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern.

ABSTRACT: SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146-1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.

SUBMITTER: Moreira-Soto A 

PROVIDER: S-EPMC8451950 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern.

Moreira-Soto Andres A   Arguedas Mauricio M   Brenes Hebleen H   Buján Willem W   Corrales-Aguilar Eugenia E   Díaz Cecilia C   Echeverri Ann A   Flores-Díaz Marietta M   Gómez Aarón A   Hernández Andrés A   Herrera María M   León Guillermo G   Macaya Román R   Kühne Arne A   Molina-Mora José Arturo JA   Mora Javier J   Sanabria Alfredo A   Sánchez Andrés A   Sánchez Laura L   Segura Álvaro Á   Segura Eduardo E   Solano Daniela D   Soto Claudio C   Stynoski Jennifer L JL   Vargas Mariángela M   Villalta Mauren M   Reusken Chantal B E M CBEM   Drosten Christian C   Gutiérrez José María JM   Alape-Girón Alberto A   Drexler Jan Felix JF  

Frontiers in medicine 20210906

SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhi  ...[more]

Similar Datasets

Unknown Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.
| S-EPMC9981790 | biostudies-literature
Unknown Research progress on vaccine efficacy against SARS-CoV-2 variants of concern.
| S-EPMC9115786 | biostudies-literature
Unknown Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.
| S-EPMC8378063 | biostudies-literature
Unknown Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants.
| S-EPMC9129155 | biostudies-literature
Unknown Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
| S-EPMC9080080 | biostudies-literature
Unknown Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
| S-EPMC8212047 | biostudies-literature
Unknown Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
| S-EPMC9291373 | biostudies-literature
Unknown Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern.
| S-EPMC8880232 | biostudies-literature
Unknown Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
| S-EPMC10104891 | biostudies-literature
Unknown Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
| S-EPMC8907979 | biostudies-literature